Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

AltaRex's OvaRex shows efficacy and safety in phase II trial

March 7, 2001

NeoPharm and NCI expand collaboration for anticancer agent

March 6, 2001

NeoPharm's CRADA agreement for IL-13 receptor research extended

March 1, 2001

Positive quality-of-life and survival results reported for Maxim's Ceplene

March 1, 2001

FDA requests further information for Campath BLA

Feb. 23, 2001

Vical broadens clinical development of Allovectin-7

Feb. 22, 2001

Therion Biologics and the NCI move CEA-TRICOM cancer vaccine to phase I

Feb. 22, 2001

Phase II trials of SMART 1D10 antibody begin in non-Hodgkin's lymphoma

Feb. 21, 2001

Virulizin granted orphan drug status by FDA

Feb. 20, 2001

Distribution agreement for Pacis BCG terminated by UroCor and BioChem Pharma

Feb. 20, 2001

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...